Patheon (PTHN) Receiving Somewhat Positive News Coverage, Report Finds

Media coverage about Patheon (NYSE:PTHN) has trended somewhat positive this week, according to Accern Sentiment Analysis. The research group identifies positive and negative news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Patheon earned a news sentiment score of 0.17 on Accern’s scale. Accern also gave headlines about the company an impact score of 46.9225423679959 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

Shares of Patheon (PTHN) opened at $34.98 on Friday. Patheon has a 52 week low of $23.72 and a 52 week high of $35.13. The company has a quick ratio of 0.91, a current ratio of 1.65 and a debt-to-equity ratio of -7.33. The company has a market cap of $5,080.00 and a price-to-earnings ratio of 46.03.

TRADEMARK VIOLATION NOTICE: This story was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this story on another domain, it was illegally copied and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be read at https://www.dispatchtribunal.com/2018/01/13/patheon-pthn-receiving-somewhat-positive-news-coverage-report-finds.html.

About Patheon

Patheon N.V. is a provider of outsourced pharmaceutical development and manufacturing services. The Company’s segments include Drug Product Services (DPS), Pharmaceutical Development Services (PDS) and Drug Substance Services (DSS). The DPS segment is engaged in manufacturing and packaging for approved prescription, over-the-counter (OTC) and nutritional products.

Insider Buying and Selling by Quarter for Patheon (NYSE:PTHN)

Receive News & Ratings for Patheon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Patheon and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply